Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally advanced or metastatic gastric cancer.

Clinical Trial Description

Approximately 6054 patients will be enrolled to evaluate the safety and preliminarily efficacy of MRG003. Patients will receive 2.0 mg/kg dose of MRG003 intravenously every 3 weeks (Q3W) and may receive up to 24 months of MRG003 if there is evidence of clinical benefit to the patients. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05188209
Study type Interventional
Source Shanghai Miracogen Inc.
Contact Program Director
Phone 86-21-61637960
Email [email protected]
Status Recruiting
Phase Phase 2
Start date May 24, 2021
Completion date August 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02650375 - Study of Metatinib Tromethamine Tablet Phase 1
Recruiting NCT04492488 - A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer Phase 1/Phase 2
Completed NCT01512745 - Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Phase 3